摘要
目的研究血清可溶性血管内皮生长因子受体-1(sFlt1)、血管内皮生长因子(VEGF)、鳞状细胞癌抗原(SCC-Ag)水平检测在子宫内膜癌患者预后评估中的应用价值。方法选取2018年3月—2022年6月于本院治疗的子宫内膜增厚患者为观察1组(n=50例),选取同期于本院治疗的子宫内膜癌患者视为观察2组(n=48例),另选取本院健康体检者为健康组(n=52),比较3组血清sFlt1、VEGF、SCC-Ag水平。48例子宫内膜癌患者中,癌细胞发生转移为转移组(n=21例)、未发生转移为未转移组(n=27例),比较不同预后患者血清sFlt1、VEGF、SCC-Ag水平,同时绘制受试者工作特征(ROC)曲线评估以上指标在子宫内膜癌患者预后的价值。结果观察2组血清sFlt1、VEGF、SCC-Ag水平均高于观察1组、健康组,且观察1组指标均高于健康组,差异有统计学意义(P<0.05);不同预后的子宫内膜癌患者中,转移组血清sFlt1水平低于健康组,VEGF、SCC-Ag水平高于健康组,差异有统计学意义(P<0.05);ROC曲线分析显示联合AUC为0.884,高于单一血清sFlt1、VEGF、SCC-AgAUC的0.838、0.868、0.852,且联合诊断敏感度、特异度分别为95.24%、81.48%。结论血清sFlt1、VEGF、SCC-Ag水平均具有显著预测效能,且联合预测子宫内膜癌的效能更佳,临床血清sFlt1、VEGF、SCC-Ag可作为预测患者预后的指标,为后续治疗提供参考依据。
Objective This paper aims to study the prognostic value of serum soluble vascular endothelial growth factor receptor-1(sFlt1),vascular endothelial growth factor(VEGF)and squamous cell carcinoma antigen(SCC-Ag)levels in patients with endometrial carcinoma.Methods A total of 50 patients with endometrial thickening(observation group 1)and 48 patients with endometrial carcinoma(observation group 2)treated in the hospital were selected between March 2018 and June 2022.Meanwhile,52 healthy individuals were selected as the healthy group.Serum sFlt1,VEGF and SCC-Ag levels in the three groups were compared.According to presence or absence of metastasis,48 patients with endometrial carcinoma were divided into metastasis group(n=21)and non-metastasis group(n=27).Serum sFlt1,VEGF and SCC-Ag levels of patients with differ⁃ent prognosis were compared.The receiver operating characteristic(ROC)curve was plotted to evaluate the prognostic value of the above indicators in patients with endometrial carcinoma.Results The levels of serum sFlt1,VEGF and SCC-Ag in observation group 2 were higher than those in observation group 1 and healthy group,and the indexes in observation group 1 were higher than those in healthy group,with the difference statistically significant(P<0.05).In patients with endometrial cancer with different prognosis,serum sFlt1 level in metastatic group was lower than that in healthy group,VEGF and SCC-Ag level was higher than that in healthy group,and the difference was statistically significant(P<0.05).ROC analysis showed that the combined AUC was 0.884,which was higher than 0.838,0.868 and 0.852 of single serum sFlt1,VEGF and SCC-AgAUC,and the combined diagnostic sensitivity and specificity were 95.24%and 81.48%,respectively.Conclusion Serum sFlt1,VEGF and SCC-Ag levels can be used for prognosis of patients with endometrial carcinoma,and joint prognosis of the three can achieve better perform⁃ance,thereby providing reference for subsequent treatment.
作者
徐燕
孙勃
徐小晶
XU Yan;SUN Bo;XU Xiao-jing(Obstetrics and Gynecology Department,Nanyang Central Hospital,Henan 473000,China)
出处
《中国卫生检验杂志》
CAS
2023年第18期2245-2247,2259,共4页
Chinese Journal of Health Laboratory Technology
基金
2020年河南省医学科技攻关计划项目(LHGJ2020-0834)。
关键词
子宫内膜癌
可溶性血管内皮生长因子受体-1
血管内皮生长因子
鳞状细胞癌抗原
预后评估
Endometrial carcinoma
Soluble vascular endothelial growth factor receptor-1
Vascular endothelial growth factor
Squamous cell carcinoma antigen
Prognosis evaluation